Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein

被引:29
作者
Caslini, C
Serna, A
Rossi, V
Introna, M
Biondi, A
机构
[1] Univ Milano Bicocca, Pediat Clin, Ctr Ric M Tettamanti, Monza, Italy
[2] Osped Riuniti Bergamo, Div Ematol, Lab Terapia Cellulare G Lanzani, Bergamo, Italy
关键词
MLL-AF4; cell cycle; differentiation;
D O I
10.1038/sj.leu.2403321
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute lymphoblastic leukemia ( ALLs) expressing MLL-AF4, the fusion product of t(4; 11)(q21; q23), show marked leucocytosis and extramedullary disease in multiple organs, respond poorly to chemotherapy and have poor prognosis. In vitro, leukemic cells with the t( 4; 11) show resistance to serum deprivation-induced or interferon gamma-regulated CD95-mediated apoptosis. In addition, t( 4; 11) cells have prolonged doubling time and lower percentage of cells in cycle compared to non-t(4; 11) B lineage cell lines. In this study, we examine the time- and level-dependent effects of MLL-AF4 conditional expression on cell cycle and differentiation of myelomonocytic leukemia cell line U937. By varying the concentration of tetracycline in growth media, we found that increasing levels of MLL-AF4 expression result in a progressive decrease in growth rate and fraction of S phase cells, paralleled by an increase in percentage of cells expressing CD11b. Our results demonstrate a dosage-dependent effect of MLL-AF4 fusion oncoprotein on cell cycle progression, with increasing expression levels resulting in the accumulation in G1, prolonged doubling time, both findings that might be responsible for the increased resistance to etoposide-mediated cytotoxicity. We propose the cell cycle control exerted by MLL-AF4 may be responsible of resistance to cell-death promoting stimuli in leukemia carrying the t( 4; 11) translocation.
引用
收藏
页码:1064 / 1071
页数:8
相关论文
共 43 条
[1]   Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins [J].
Ayton, PM ;
Cleary, ML .
ONCOGENE, 2001, 20 (40) :5695-5707
[2]   Biological and therapeutic aspects of infant leukemia [J].
Biondi, A ;
Cimino, G ;
Pieters, R ;
Pui, CH .
BLOOD, 2000, 96 (01) :24-33
[3]  
BIONDI A, 1993, BLOOD, V82, P2943
[4]   Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis [J].
Boer, J ;
Bonten-Surtel, J ;
Grosveld, G .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (03) :1236-1247
[5]   The HRX proto-oncogene product is widely expressed in human tissues and localizes to nuclear structures [J].
Butler, LH ;
Slany, R ;
Cui, XM ;
Cleary, ML ;
Mason, DY .
BLOOD, 1997, 89 (09) :3361-3370
[6]   The amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffolds [J].
Caslini, C ;
Alarcòn, AS ;
Hess, JL ;
Tanaka, R ;
Murti, KG ;
Biondi, A .
LEUKEMIA, 2000, 14 (11) :1898-1908
[7]   The amino terminus of the mixed lineage leukemia protein (MLL) promotes cell cycle arrest and monocytic differentiation [J].
Caslini, C ;
Shilatifard, A ;
Yang, LP ;
Hess, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (06) :2797-2802
[8]   TOPOISOMERAS-SPECIFIC DRUG SENSITIVITY IN RELATION TO CELL-CYCLE PROGRESSION [J].
CHOW, KC ;
ROSS, WE .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (09) :3119-3123
[9]  
DELBINO G, 1994, LEUKEMIA, V8, P281
[10]   MLL rearrangements in haematological malignancies: Lessons from clinical and biological studies [J].
DiMartino, JF ;
Cleary, ML .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (03) :614-626